glp 1 shortage ending Hims & Hers stock falls 25% as FDA curtails compounded GLP-1s 🚨 FDA Moves to Permanently

Such a sale would be otherwise denied

Protection Against Toxin- or Medication-Related Injury: Some research indicates that BPC-157 may help counteract tissue damage from certain medications, such as NSAIDs, or toxins, especially in the gut and soft tissues

Chloramphenicol-induced oxidative stress in human neutrophils

Tier 1: Pure GLP-1, injectable, FDA-approved Exenatide (Byetta, Bydureon) Liraglutide (Victoza, Saxenda) Lixisenatide (Adlyxin) Dulaglutide (Trulicity) Semaglutide (Ozempic, Wegovy) Efpeglenatide (Eperzan) Tier 2: Pure GLP-1, oral, FDA-approved Semaglutide (Rybelsus) Orforglipron (Orfoglip) Tier 3: Dual or triple agonist, FDA-approved Tirzepatide (Mounjaro, Zepbound) Retatrutide (Retara) Tier 4: Compounded (not FDA-approved) Compounded semaglutide Compounded tirzepatide Compounded semaglutide + B12 Compounded tirzepatide + B12 The tier system reflects regulatory status, not efficacy